Rituximab
Cd20 (Clusters Of Differentiation 20) Inhibitors
Sold as Rixathon · Blitzima · Ituxredi · MabThera · Ritemvia
- Drug class
- Cd20 (Clusters Of Differentiation 20) Inhibitors
- Availability
- See label
- Routes
- Intravenous, Subcutaneous
- Markets covered
- 3
- Products on record
- 30
Overview
Rituximab is an active pharmaceutical ingredient in the Cd20 (Clusters Of Differentiation 20) Inhibitors group (L01FA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 15 | May 29, 2026 |
| CA Canada | Health Canada | 8 | May 28, 2026 |
| EU European Union | EMA | 7 | October 6, 2025 |
GBUnited Kingdom· MHRA
15 products
Uses
Non-Hodgkin’s lymphoma (NHL) Truxima is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. Truxima maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.
Truxima monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemo-resistant or are in their second or subsequent relapse after chemotherapy. Truxima is indicated for the treatment of adult patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Truxima in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt- like lymphoma (BLL).
CACanada· Health Canada
8 products
Uses
Non-Hodgkin’s Lymphoma (NHL) RITUXAN (rituximab for injection) is indicated for: • the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma. • the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.
• the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non- Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. • the maintenance treatment of patients with follicular non-Hodgkin’s lymphoma who have responded to induction therapy with either CHOP or CHOP plus Rituxan.
• single-agent maintenance treatment of previously untreated patients with advanced follicular non- Hodgkin’s lymphoma with high tumour burden and who have responded to induction therapy with either CHOP plus RITUXAN or CVP plus Rituxan.
EUEuropean Union· EMA
7 products
Uses
Non-Hodgkin’s lymphoma (NHL) Rixathon is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. Rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.
Rixathon monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. 3 Rixathon is indicated for the treatment of adult patients with CD20 positive diffuse large B-cell non- Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).
Drug interactions
Known interactions involving Rituximab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB518080007 · revised May 22, 2026
- [2]Health Canada (DPD) · 02241927 · revised October 17, 2025
- [3]European Medicines Agency · EMEA/H/C/003903 · revised October 6, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.